Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$105.3 million.

  • C4 Therapeutics' Income towards Parent Company fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
  • Per C4 Therapeutics' latest filing, its Income towards Parent Company stood at -$105.3 million for FY2024, which was up 20.51% from -$132.5 million recorded in FY2023.
  • C4 Therapeutics' Income towards Parent Company's 5-year high stood at -$66.3 million during FY2020, with a 5-year trough of -$132.5 million in FY2023.
  • Its 3-year average for Income towards Parent Company is -$122.0 million, with a median of -$128.2 million in 2022.
  • In the last 5 years, C4 Therapeutics' Income towards Parent Company tumbled by 94.54% in 2020 and then increased by 20.51% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Income towards Parent Company stood at -$66.3 million in 2020, then decreased by 26.47% to -$83.9 million in 2021, then tumbled by 52.79% to -$128.2 million in 2022, then decreased by 3.37% to -$132.5 million in 2023, then rose by 20.51% to -$105.3 million in 2024.